Asian biotech out-licensing deals
As of 2026-11-01, Drugnews tracks 30 out-licensing deals from Chinese, Japanese, Korean and Taiwanese companies to partners outside Asia since 2026-04-01, with US$3.2475 billion in disclosed upfront payments; the largest upfront was Dizal Pharmaceutical Co., Ltd. → AstraZeneca (Zegfrovy / sunvozertinib, US$600m).
30 deals
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | GC Biopharma Corp.; Hanmi Pharm Co., Ltd.GC Biopharma · Hanmi | BioMarin Pharmaceutical Inc. | HM15421 / GC1134A (LA-GLA) | Enzymes / proteins | Worldwide excluding Korea | US$70m | US$475m | Source · 2 |
| 2026-10-19 | Hansoh Pharmaceutical Group Co., Ltd. | Roche | 兩項未具名臨床前ADC及以羅氏提出靶點開發的多項ADC計畫 | ADC / conjugates | 全球，不含中國大陸、香港、澳門及台灣；翰森保留上述地區權利 | US$400m | Undisclosed | Source · 2 |
| 2026-10-19 | METiS TechBio | Eli Lilly and Company | 組織特異性LNP遞送合作；AiLNP平台（未披露具名藥物） | Delivery platforms | Undisclosed | Undisclosed | Undisclosed | Source · 2 |
| 2026-10-13 | Wuhan Hiteck Biological Pharma Co., Ltd. | Visara, Inc. | HT006.2.2滴眼液／VIS-102 | Enzymes / proteins | 全球，不含大中華區 | Undisclosed | Undisclosed | Source · 2 |
| 2026-10-09 | Triastek, Inc.; Triastek (Shanghai) Limited | Janssen Pharmaceutica NV (Johnson & Johnson) | MED&SSE三維藥物列印及3DμS-OM口服大分子遞送平台合作（未披露具名藥物） | Delivery platforms | Undisclosed | Undisclosed | Undisclosed | Source · 2 |
| 2026-10-08 | Defand Therapeutics | Roche | 多靶點分子膠降解劑研究與授權計畫（未披露具名藥物） | Small molecules | 全球獨家商業化權利 | Undisclosed | Undisclosed | Source · 2 |
| 2026-10-07 | Asieris Pharmaceuticals | Theramex | CEVIRA／APL-1702（hexaminolevulinate hydrochloride光動力治療系統） | Other / unspecified | 全部歐洲國家、澳大利亞、紐西蘭及土耳其；亞虹保留其他地區 | US$15m | Undisclosed | Source · 2 |
| 2026-10-02 | Abogen Biosciences | Novartis | ABO2203及其他RNA平台衍生計畫的獨家選擇權 | RNA therapeutics | 全球獨家ABO2203授權；其他計畫為獨家授權選擇權 | US$575m | Undisclosed | Source · 2 |
| 2026-09-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Novo Nordisk A/S | HRS-1596 | Other / unspecified | 全球，排除中國大陸、香港、澳門及台灣 | US$300m | US$2.6bn | Source · 2 |
| 2026-09-28 | Tanabe Pharma Corporation | Tolerance Bio, Inc. | MT-2990 / TLB-33 | Antibodies | 全球開發權；日本以外獨家商業化權，日本商業化權由 Tanabe 保留 | Undisclosed | Undisclosed | Source · 2 |
| 2026-09-28 | SciBrunch Therapeutics Co., Ltd. | Merck & Co., Inc. | SPR2015 | Small molecules | 全球 | US$400m | US$2.13bn | Source · 2 |
| 2026-09-24 | InnoCare Pharma Limited | Eli Lilly and Company | 最多5個未披露靶點之藥物發現計畫 | Other / unspecified | Undisclosed | Undisclosed | Undisclosed | Source · 2 |
| 2026-09-22 | Boomray Pharmaceuticals Co., Ltd. | Novartis Pharma AG | 未披露代號之放射性配體治療資產 | Radiopharmaceuticals | 全球 | Undisclosed | US$900m | Source · 2 |
| 2026-09-16 | Shanghai Escugen Biotechnology Co., Ltd. | Sovran Bio, Inc. | 未披露代號之泛腫瘤雙特異性ADC共同開發計畫 | ADC / conjugates | Undisclosed | Undisclosed | Undisclosed | Source · 2 |
| 2026-09-03 | HUTCHMED Limited (subsidiary of HUTCHMED (China) Limited) | GlaxoSmithKline Intellectual Property (No. 4) Limited (GSK subsidiary) | HMPL-A830（附另一項較早期ATTC資產優先議約權） | ADC / conjugates | 全球，排除中國大陸、香港、澳門及台灣 | US$110m | US$1.295bn | Source · 2 |
| 2026-09-02 | Alteogen Inc. | Novartis | ALT-B4 (berahyaluronidase alfa) / Hybrozyme-enabled SC formulations of multiple undisclosed Novartis products | Enzymes / proteins | Undisclosed | Undisclosed | US$3.223bn | Source · 2 |
| 2026-09-01 | Simcere Pharmaceutical Group Limited / Simcere Zaiming | F. Hoffmann-La Roche Ltd | SIM0660 | Antibodies | 全球 | US$75m | US$1.53bn | Source · 2 |
| 2026-08-28 | DUALITYBIO Inc. (DualityBio) | Genentech, Inc. | DUPAC platform-derived oncology ADC collaboration programs | ADC / conjugates | Worldwide exclusive license to collaboration ADCs | US$45m | Undisclosed | Source · 2 |
| 2026-08-25 | Haisco Pharmaceutical Group Co., Ltd. | Sentivera Therapeutics | Undisclosed oral small-molecule autoimmune / type 2 inflammation program | Small molecules | Worldwide excluding mainland China, Hong Kong, Macao and Taiwan | US$40m | Undisclosed | Source · 2 |
| 2026-08-18 | Tanabe Pharma Corporation | LEO Pharma A/S | Dersimelagon / MT-7117 | Small molecules | 全球開發與商業化權 | Undisclosed | Undisclosed | Source · 2 |
| 2026-08-03 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Pathos AI, Inc. | JSKN016 | ADC / conjugates | Worldwide excluding mainland China, Hong Kong, Macau and Taiwan | US$125m | US$2.093bn | Source · 2 |
| 2026-07-14 | Dizal Pharmaceutical Co., Ltd. | AstraZeneca | Zegfrovy / sunvozertinib | Small molecules | Worldwide development and commercialization rights | US$600m | Undisclosed | Source · 2 |
| 2026-07-14 | Innovent Biologics (Suzhou) Co., Ltd.; Fortvita Biologics (USA), Inc. | Spero Therapeutics, Inc. | SP001 / IBI355 and related anti-CD40L compounds | Antibodies | Worldwide excluding mainland China, Taiwan, Hong Kong and Macau | US$35m | US$1.1bn | Source · 2 |
| 2026-07-14 | Shanghai Hansoh Biomedical Co., Ltd. | Avere Therapeutics, Inc. | HS-20118 / AVR-001 | Peptides | Worldwide excluding mainland China, Hong Kong, Macao and Taiwan | US$90m | Undisclosed | Source · 2 |
| 2026-07-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | AstraZeneca | TQC3721; certain future development programs | Small molecules | TQC3721 outside China; certain future development programs worldwide | US$200m | US$1.9bn | Source · 2 |
| 2026-07-02 | CSPC Pharmaceutical Group Limited | AstraZeneca | Two renal-disease siRNA target programs | RNA therapeutics | Option for worldwide or ex-China exclusive rights, depending on program; CSPC retains China rights to one candidate | US$30m | Undisclosed | Source · 2 |
| 2026-06-02 | Everest Medicines | Travere Therapeutics, Inc. | Civorebrutinib / EVER001 | Small molecules | All markets outside China and certain countries in East and Southeast Asia | US$112.5m | Undisclosed | Source · 2 |
| 2026-06-01 | Haisco Pharmaceutical Technology (Lhasa) Co., Ltd. | Eli Lilly and Company | Up to five undisclosed innovative small-molecule target programs | Small molecules | Worldwide exclusive rights or worldwide excluding mainland China, Hong Kong, Macao and Taiwan, depending on program | Undisclosed | US$3.054bn | Source |
| 2026-06-01 | Oscotec Inc. | Agios Pharmaceuticals, Inc. | Cevidoplenib (SKI-O-703) | Small molecules | Worldwide; Oscotec South Korea opt-in after Phase 3 results | US$25m | US$665m | Source · 2 |
| 2026-04-01 | Daiichi Sankyo Company, Limited | Nuvation Bio Inc. | Safusidenib / DS-1001 | Small molecules | 本次追加日本權利；修約後 Nuvation 持有全球獨家開發及商業化權 | Undisclosed | Undisclosed | Source · 2 |
No matching deals. Clear filters to view all transactions.
Frequently asked questions
Which Asian biotech out-licensing deals had the largest upfront payments in 2026?
Dizal Pharmaceutical Co., Ltd. → AstraZeneca (Zegfrovy / sunvozertinib): US$600m; Abogen Biosciences → Novartis (ABO2203及其他RNA平台衍生計畫的獨家選擇權): US$575m; Hansoh Pharmaceutical Group Co., Ltd. → Roche (兩項未具名臨床前ADC及以羅氏提出靶點開發的多項ADC計畫): US$400m; SciBrunch Therapeutics Co., Ltd. → Merck & Co., Inc. (SPR2015): US$400m Rankings cover the tracked dataset and disclosed upfront payments only.
How many China out-licensing deals are tracked?
24 of 30 tracked deals involve licensors from China, including Hong Kong. 24 were announced in 2026. This is a sourced subset, not a census of all transactions.
Which drug types appear most often in Asian out-licensing deals?
Small molecules: 10; ADC / conjugates: 5; Antibodies: 3; Enzymes / proteins: 3; Other / unspecified: 3; Delivery platforms: 2; RNA therapeutics: 2; Peptides: 1; Radiopharmaceuticals: 1. Each agreement is assigned one modality category; multi-asset agreements count once.
Which Western pharma companies license the most Asian assets?
AstraZeneca (3); Eli Lilly and Company (3). Counts are agreements per named US, Canadian or European counterparty in this dataset, not individual asset counts or a market-wide ranking. Subsidiaries and parents are not combined.
How is this data sourced?
30 agreements are compiled from linked company announcements, filings and attributed transaction sources dated 2026-04-01–2026-10-29. Each row retains a source URL, source date and check timestamp in the downloadable data. Blank amounts remain undisclosed; US$3.2475 billion covers 18 disclosed upfronts, and US$20.965 billion covers 12 disclosed potential total values. Conditional milestones are not received cash. The dataset is a growing, non-exhaustive subset; original asset and territory wording is retained.